Integration Pattern of Human Papillomavirus Is a Strong Prognostic Factor for Disease-Free Survival After Radiation Therapy in Cervical Cancer Patients

Joo, Jungnam; Shin, Hyung Shik; Park, Boram; Park, Seog-Yun; Yoo, Chong-Woo; Yoon, Kyong–Ah; Kong, Sun‐Young; Kim, Youn‐Jae; Kim, Sang Soo; Kim, Joo-Young

doi:10.1016/j.ijrobp.2017.02.226

Cited by 12 publications

(12 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It also has been reported that residual HPV DNA is clinically useful as a new marker to predict local recurrence after conization for cervical intraepithelial neoplasia14–18 and after RT for invasive cervical carcinoma 19–28. In the study conducted by the University of the Ryukyus in Japan, local recurrence rate was significantly higher in patients with persistent HPV than in patients cleared for HPV who were treated with RT (34% vs 7.1%).…”

Section: Introductionmentioning

confidence: 98%

Multicentre, randomised controlled trial of adjuvant chemotherapy in cervical cancer with residual human papilloma virus DNA following primary radiotherapy or chemoradiotherapy: a study protocol

Wang

Ouyang

et al. 2019

BMJ Open

View full text Add to dashboard Cite

IntroductionThe role of adjuvant chemotherapy after radical radiotherapy (RT) or chemoradiotherapy (CRT) in cervical cancer awaits further confirmation. Evidences have shown that persistent human papilloma virus (HPV) DNA in exfoliated cell post-RT is a potential biomarker of subclinical residual disease and thus increases the risk of recurrence. In this prospective, multicentre, randomised controlled trial, we will use HPV DNA in exfoliated cell to identify patients with cervical cancer who received definitive RT or CRT with higher risk of relapse for adjuvant chemotherapy.Methods and analysisEligible patients with histologically confirmed cervical cancer stage IIA2 to IVA of the International Federation of Gynaecology and Obstetrics, adequate organ function and no locoregional disease or distant metastasis after completion of primary treatment will be screened for HPV DNA in exfoliated cell at 1 month post-RT. Patients with undetectable HPV DNA will undergo standard surveillance. Patients with detectable HPV DNA will be randomly assigned to either adjuvant chemotherapy with docetaxel and nedaplatin for four cycles (arm 1) or observation (arm 2). Patients will be stratified for primary treatment (RT vs CRT). The primary endpoint is relapse-free survival.Ethics and disseminationThis protocol received a favourable ethical opinion from the Ethics Committee of the Second Affiliated Hospital of Fujian Medical University on 6 February, 2018, (No. 28). The trial results will be published in peer-reviewed journals and presented in conferences. A summary of the findings will be made available to participants.Trial registration numberChiCTR-IIR-17012655; Pre-results.

show abstract

Section: Introductionmentioning

confidence: 98%

Multicentre, randomised controlled trial of adjuvant chemotherapy in cervical cancer with residual human papilloma virus DNA following primary radiotherapy or chemoradiotherapy: a study protocol

Wang

Ouyang

et al. 2019

BMJ Open

View full text Add to dashboard Cite

show abstract

“…4 Several patient-, tumor -or treatment-related variables have been found to be predictive of outcome after RT alone or CCRT, such as age, HPV status, tumor size, histology, FIGO stage, LN involvement, and initial [ 18 F]FDG-PET/CT avidity. [5][6][7] Associations between the hemoglobin (Hb) count recorded during CCRT and patient outcome, such as OS and RFS, have also been reported in various retrospective trials but with conflicting results. [8][9][10][11] Although the only prospective trial evaluating the benefit of correcting the Hb count via red blood cell (RBC) transfusions in CC was clearly underpowered for this purpose, the study findings suggested that increasing the Hb count to >12 g/dL could decrease the risk of local relapse.…”

Section: Introductionmentioning

confidence: 99%

Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, the response to radiotherapy varies widely among patients, underscoring the need to identify biomarkers to predict patients’ treatment outcome. Recently, the integration pattern of human papillomavirus (HPV) has been investigated as a promising biomarker for cervical cancer patients 1 .…”

Section: Introductionmentioning

confidence: 99%

The association of integration patterns of human papilloma virus and single nucleotide polymorphisms on immune- or DNA repair-related genes in cervical cancer patients

Joo

Omae

Hitomi

et al. 2019

Sci Rep

Self Cite

View full text Add to dashboard Cite

The present study investigated the association between single nucleotide polymorphisms (SNPs) in immune- or DNA repair-related genes and the integration pattern of human papillomavirus (HPV), a promising prognostic marker in cervical cancer. The HPV integration patterns of cervical cancer patients were determined by polymerase chain reaction and in situ hybridization, and categorized as episomal (group A), single-copy or multi-copy tandem repetition integrated (group B), and undetectable HPV types (group C). After sample and SNP quality control, 166,505 SNPs in 161 samples (38, 111, and 12 patients in groups A, B, and C, respectively) were examined. None of the SNPs reached genome-wide significance, and several candidate SNPs for future study were selected, including rs10999435 on chromosome 10q22, rs1322054 on chromosome 9q32-33, and rs10902171 on chromosome 11p15. Luciferase assay identified rs1322054 as the primary functional variant to regulate gene expression in immune cell. Further studies are needed to determine the genetic background of different integration patterns of HPV in cervical cancer patients.

show abstract

Integration Pattern of Human Papillomavirus Is a Strong Prognostic Factor for Disease-Free Survival After Radiation Therapy in Cervical Cancer Patients

Cited by 12 publications

References 11 publications

Multicentre, randomised controlled trial of adjuvant chemotherapy in cervical cancer with residual human papilloma virus DNA following primary radiotherapy or chemoradiotherapy: a study protocol

Multicentre, randomised controlled trial of adjuvant chemotherapy in cervical cancer with residual human papilloma virus DNA following primary radiotherapy or chemoradiotherapy: a study protocol

Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy

The association of integration patterns of human papilloma virus and single nucleotide polymorphisms on immune- or DNA repair-related genes in cervical cancer patients

Contact Info

Product

Resources

About